Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.37 |
| ▸ | CDC7 | O00311 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559145 | 0.84 | ADORA2A (0.56) | ADORA2AMEN1GAAKMT2AADORA1 | |
| SCHEMBL4559176 | 0.79 | SIRT2 (0.45) | ADORA2AMEN1GAAKMT2AADORA1 | |
| SCHEMBL5686383 | 0.78 | BTK (0.41) | ADORA2AMEN1GAAKMT2AADORA1 | |
| SCHEMBL16465331 | 0.78 | GAA (0.45) | ADORA2AMEN1GAAKMT2AADORA1 | |
| SCHEMBL5686147 | 0.75 | MGMT (0.45) | ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL5686125 | 0.75 | PARP10 (0.50) | ADORA2AGAA | |
| SCHEMBL5689008 | 0.75 | LMNA (0.43) | ADORA2AMEN1GAAKMT2AADORA1 | |
| SCHEMBL28145391 | 0.72 | ADORA2A (0.59) | ADORA2AXDHADORA1SCN9ANUDT1 | |
| SCHEMBL4559387 | 0.71 | LMNA (0.45) | ADORA2ASCN9APOLBALDH1A1 | |
| SCHEMBL16465321 | 0.69 | KMT2A (0.45) | XDHMEN1GAAKMT2ACDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | ADORA2A 1722/4885XDH 1047/4885MEN1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.